Clinical Trial Update: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain [Phase 2]

View source ↗

Summary

This entry reports a Phase 2 study of LY4065967 for diabetic peripheral neuropathy pain under a Chronic Pain Master Protocol. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy

Drugs mentioned

• LY4065967

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetic Peripheral Neuropathic Pain | Phase 2 | Status: RECRUITING